BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical & Diagnostic

IMPACT Therapeutics, Pharmanovia’s Senaparib Secures EU Panel Backing for Ovarian Cancer

MPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based...

September 21, 2026 | News

Massive Bio Targets South Korea Expansion for AI-Powered Oncology Trial Matching

US healthtech company Massive Bio has appointed international business development consultancy Intralink to support its expansion into South Korea and buil...

September 21, 2026 | News

Why 10,000 Koreans a Year Still Fly Abroad for Stem Cell Treatment

METHOD IN BRIEF This feature expands entry 21 of our year-end count, 2026 in 26 Numbers. Every figure is cited to a regulator publication, offi...

September 21, 2026 | Analysis

Ferronova’s Nanoparticle Platform Shows Promise for More Precise Gastric and Oesophageal Cancer Surgery

Australian medical technology company Ferronova has announced preliminary findings from the MAGMAP multi-centre trial involving 62 gastric and oesopha...

September 17, 2026 | News

Takeda’s Zasocitinib Receives US FDA Priority Review for Plaque Psoriasis

-Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for za...

September 16, 2026 | News

IonOpticks Launches Aurora Series 5 to Boost Robustness in High-Throughput Proteomics

New CoreJet™ integrated emitter technology and a redesigned nanoZero® union combine proven Aurora Series® performance with a step-change in r...

September 15, 2026 | News

US FDA Approves Telix’s Pixclara as First FET-PET Imaging Drug for Brain Cancer

Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). Approval addresses a significant unmet need, helping physicians ...

September 15, 2026 | News

Accro Bioscience’s AC-101 Enters China’s Rare Disease Innovative Drug Pilot Programme for Blau Syndrome

Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program (the "Caring...

September 15, 2026 | News

Bausch + Lomb Secures European CE Mark for Next-Generation SeeLyra Femtosecond Laser

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced European C...

September 14, 2026 | News

Exegenesis Bio, Modalis Partner to Advance CRISPR-Based DMD Therapy MDL-201

Exegenesis Bio and Modalis Therapeutics Corporation (TOKYO: 4883; "Modalis") announced that they have signed a research collaboration and license agr...

September 14, 2026 | News

Gan&Lee Doses First Participant in Phase I Trial of Once-Weekly Oral GLP-1 Candidate GZC8072

Gan&Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan&Lee) announced that the first participant has been dosed in a First-In-Human (FIH...

September 11, 2026 | News

Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity

- This trial marks the fourth Phase I peptide study for Ascletis this year. - ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at ste...

September 10, 2026 | News

CorrectSequence’s Base-Editing Therapy Shows Durable Response Across Diverse β-Hemoglobinopathy Patients

Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT pati...

September 09, 2026 | News

Dimerix Secures A$34M Non-Dilutive Funding to Advance Kidney Disease Pipeline Subheadline:

Dimerix successfully enters into non-dilutive facility agreements to access A$34 million[1] with a syndicate of Australian and U.S. independent lend...

September 07, 2026 | News

Stay Connected